



FAMILY OFFICE DAY

CAPITAL MARKET CONFERENCES

INVITATION

www.familyofficeday.at



FAMILY OFFICE DAY

CAPITAL MARKET CONFERENCES

About the Family Office Day

The Capital Market Conferences Family Office Day are the first and unique finance platform for Family Offices, Foundations, HNWI and Institutional Investors in Austria with a very rapidly expanding international investor network.

Since 2015 we have successfully organized 39 Capital Market Conferenes and 39 Investor Lunch Presentations in the DACH region and hosted more than 400 international companies and 4,000 Family Offices, Foundations, HNWI and Institutional Investors from the DACH region, Liechtenstein, Monaco, UK, Israel and Hongkong.

By organizing these symposiums we not only offer our investor target group an international platform for an exchange of views and discussions but we also contribute to strengthen the Austrian Capital Market permanently.

The speakers come from Austrian and international companies of various sectors. They are invited to present their business models and future projects to the investors. Each conference also includes an elevator pitch for start-ups.

Participation is by invitation only!

Hosted by

advantage
FINANCE

Advantage Finance

Sabine Duchaczek, Managing Director

phone: +43 664 454 7771 | e-mail: duchaczek@advantage.co.at

website: www.advantage.co.at

INVITATION TO THE

FAMILY OFFICE DAY
21 OCTOBER 2021

HOTEL IMPERIAL
KÄRNTNER RING 16, 1015 VIENNA

At the conference the current distancing and hygiene regulations will be observed

Save the Date: Family Office Days 2021



1 December 2021: Capital Market Conference Family Office Day in Vienna & Online

2 December 2021: Family Office IMPACT Day in Vienna & Online

Due to the great interest of family offices we will organize our third Family Office IMPACT Day conference on 2 December 2021 in Vienna with live online broadcast.

The aim of this series of events is to inform family offices, foundations, HNWIs and institutional investors independently, comprehensively and with a high level about the topic of impact investing and to offer a platform in Vienna and online where investors can learn from international pioneers and experts. We want to underline the importance of the topic for the preservation of the global social- and ecosystem and to inspire more investors for the idea of impact investing, so that future generations will also benefit sustainably. Due to the good feedback from investors and companies, we organize the Family Office IMPACT Day conferences twice a year.

Participation is possible either on site at the Hotel Imperial in Vienna (investors only) or Online.

Agenda

09:00 *Registration*

09:25 *Salutation and Opening Remarks*

09:30 HBM Healthcare Investments AG, www.hbmhealthcare.com

10:00 BB Biotech AG, www.bbbiotech.ch

10:30 MagForce AG, www.magforce.com

11:00 Valneva SE, www.valneva.com

11:30 *Pause*

11:45 Cellestia Biotech AG, www.cellestia.com

12:15 Accanis Biotech F&E GmbH & Co KG, www.accanis.com

12:45 Topadur Pharma AG, www.topadur.com

12:55 We Ship Fulfillment GmbH, www.weship.at

13:05 *Curveplate*

13:15 *Lunch Break*

14:00 HanseYachts AG, www.hanseyachtsag.com

14:30 Cogia AG, www.cogia.ag

15:00 Comgest S.A., www.comgest.com

15:30 *Pause*

16:00 Edmond de Rothschild Asset Management S.A., www.edmond-de-rothschild.com

16:30 RAMFORT GmbH, www.ramfort.de

17:00 PRUVIA GmbH, www.pruvia.com

17:30 GuardBox SE, www.guardmine.com

18:00 *Closing Words and Aperó*



FAMILY OFFICE DAY

CAPITAL MARKET CONFERENCES

Partner

Direct Funding Partner
direct market plus

wiener
boerse

PARTNER



Media Partner

Absolut
research

DIE PLATTFORM FÜR INSTITUTIONELLE INVESTOREN

FAMILY OFFICE
Magazine & Events

www.familyofficemag.com

HBM Healthcare Investments AG

HBM Healthcare Investment AG invests in the human medicine, biotechnology, medical technology and diagnostics sectors and other related areas. The investment company holds and actively manages a global portfolio of promising privately-held and SMID-cap public companies. HBM Healthcare Investment AG's net assets amount to c. CHF 2.4 B. Many of the underlying companies have their lead products already available on the market or at an advanced stage of development. Portfolio companies are closely tracked and guided on their strategic directions. In large private portfolio companies, HBM Healthcare Investment AG holds board seats and takes an active role and assumes entrepreneurial responsibility together with the management team. Investments in private companies have contributed significantly to HBM Healthcare Investment AG's value creation with more than 60 trade sales and IPOs in the past decade. This renders HBM Healthcare Investments AG an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments AG has an international shareholder base and is listed on SIX – Swiss Exchange. The investment company is advised by the team of HBM Partners AG, a Swiss healthcare investor regulated by FINMA. HBM Partners AG was founded in 2001 and manages additional public funds specialized in healthcare. The team consists of over 20 experienced investment professionals with relevant expertise, scientific, industry and financial background.

Market Capitalisation:	CHF 2,473 M (31.08.2021)
Exchange Segment:	SIX – Swiss Stock Exchange, main segment, Bloomberg ticker: HBMN SW, Reuters: HBMN.S
Principal Shareholders:	International and diversified; with major shareholder between 15-20%
Sales:	Not applicable as HBM Healthcare Investment AG is an investment company
Earnings (after Taxes):	CHF 225.9 M (30.06.2021 – Q1 financial year 2021/2022)
Earnings per Share:	CHF 32.46 (30.06.2021 – Q1 financial year 2021/2022)
Dividend per Share:	CHF 12.50 (paid in September 2021)
Dividend Yield:	3.8% (June 2021)

BB Biotech AG



BB Biotech AG is a Swiss domiciled Investment Company. The shares of BB Biotech AG are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and the Stock Exchange in Milan.

BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs and is one of the world's largest investors in this sector with 27 years of experience. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential. Besides profitable larger companies, BB Biotech AG is building up its investments in promising small- and mid-cap companies. The team of investment experts is concentrating not only on established target areas such as oncology, orphan diseases and neurological indications, but also on the technologies of tomorrow that could lead to novel treatment methods with attractive therapeutic profiles and substantial economic rewards. These future technologies include RNA platforms and cell and gene therapies. A total return of 15 percent p.a. over a medium- to longer-term investment horizon is targeted. BB Biotech AG's investment portfolio usually consist of between 20 to 35 biotechnology companies.

Market Capitalisation:	EUR 4.5 B
Exchange Segment:	The shares of BB Biotech are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and the Stock Exchange in Milan
Dividend Yield:	5% (on the average price of the month of December)

MagForce AG

MagForce AG is forging new paths to treat cancer successfully and gently with its NanoTherm Therapy System. In Europe, MagForce AG's NanoTherm Therapy System has had the official approval for the treatment of brain cancers. Currently, four renowned hospitals are successfully treating brain tumor patients, three in Germany and one in Poland. Additional treatment centers in other European countries are planned.

In the US, MagForce AG is preparing the next and final stage of its pivotal clinical FDA study for the treatment of prostate cancer. Since the particles agglomerate after being instilled into the tumor, they are classified as an implant and as such the trial MagForce AG is conducting, is a medical device trial. Prostate cancer treatments in the first two stages of the study showed only minimal side effects for the patients and thereby a very good ablation of the tumor.

MagForce AG expects to achieve FDA approval in H1/2022. Commercialization will follow immediately using the three MagForce AG-owned treatment centers already operational, with further two sites to follow in 2022. Each site will be able to treat up to 750 patients per year running on two shifts which will allow to generate up to USD 15 M of gross revenue per center per year. The market potential for this therapy in the USA alone is USD 4.1 B and globally USD 10.5 B.

Market Capitalisation:	EUR ~110 M
Exchange Segment:	Scale
Principal Shareholders:	Avalon Capital One, M&G, Skagen Fund, Dr. Ben Lipps
Sales:	EUR 621,000
Earnings (after Taxes):	EUR 15,000

Valneva SE



Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company takes a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. It then applies its deep understanding of vaccine science, including its expertise across multiple vaccine modalities, as well as its established vaccine development capabilities, to develop prophylactic vaccines to address these diseases.

The company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, COVID-19 and the chikungunya virus.

Market Capitalisation:	EUR 1.26 B (15.09.2021)
Exchange Segment:	Euronext Paris, Nasdaq
Principal Shareholders:	Groupe Grimaud La Corbiere 13.72%, Bpifrance Participations SA 8.98%
Total Revenues 2020:	EUR 110.3 M
Product Sales 2020:	EUR 65.9 M
Loss (after Taxes) 2020:	EUR 64.4 M
Loss per Share 2020:	EUR 0.71

Cellestia Biotech AG



Cellestia Biotech AG is a clinical stage company based in Basel, Switzerland, developing a proprietary R&D pipeline of innovative drugs with novel Modes of Action. The company expects to complete clinical Phase 1 with CB-103, the clinical lead project, during 2020. CB-103 is a potent inhibitor of oncogene transcription to control specific forms of cancer. At present, there are no competitor compounds on the market.

In parallel Cellestia Biotech AG develops the diagnostic program to select suitable patients for this targeted therapy. The current trial is running in EU and USA, and filings for IND in China and other Asian countries underway. Treating cancer patients, CB-103 has confirmed excellent tolerability and first signs of efficacy and Cellestia Biotech AG is now launching the Phase 2 clinical program. In parallel the company is advancing the R&D pipeline towards clinical development. The market potential for CB-103 is expected to exceed one billion annual sales. The patent position is excellent with a growing patent portfolio securing exclusivity until 2039. First patent is granted in EU, USA, China and Japan and other countries.

A total of USD 50 M have been raised from private and institutional investors. David Epstein, former CEO of Novartis, joined Cellestia Biotech AG in 2018 as a private lead investor. Institutional investors are PPF, FC Capital, Partners Invest and ETP Venture Fund. For further information please contact Michael Bauer, CEO on michael.bauer@cellestia.com

Accanis Biotech F&E GmbH & Co KG



Accanis Biotech F&E GmbH & Co KG develops innovative therapeutics for the treatment of common, localized diseases using mRNA. mRNA is the new game changer which delivers the blockbuster therapeutics of the (already nearby) future. This has been impressively demonstrated by Pfizer/Biontech and Moderna with their development of mRNA-based Covid 19 vaccines.

Accanis Biotech F&E GmbH & Co KG is also developing patent protected products based on mRNA but for completely different indications. The products of the company are generated by its own platform technology called RNAViennaTM. This platform allows for the generation of proprietary mRNAs for each and any (therapeutic) protein of interest. As prototypes, Accanis Biotech F&E GmbH & Co KG has developed two lead mRNAs encoding for validated targets namely Interferon-alpha und FGF-2. Both targets are known to be effective, Interferon-alpha for actinic keratosis and non-melanoma skin cancer, FGF-2 for skin rejuvenation and atrophic scars. The company has already shown for both targets preclinical proof of concept in vivo, in living pigs.

Accanis Biotech F&E GmbH & Co KG is now looking for an investment of EUR 9 M and is offering 25 percent of the company shares for that. The EUR 9 M will be used to move the company forward to the next value inflexion point which is the successful completion of the first clinical trial and which will multiply the valuation of the company. Details for that strategy will be presented at the investment day.

HanseYachts AG



HanseYachts AG is the world's second-largest series manufacturer of sailing yachts with a hull length of 30 to 70 feet (10 to 21 meters) and is one of the top 10 motorboat manufacturers with a hull length of 30 to 54 feet (10 to 16 meters). The company produces the Hanse, Moody and Dehler brands in the sailing yacht segment and the Fjord, Sealine and Ryck brands in the motor yacht segment. In addition, the company produces sailing and motor catamarans under the brand Privilège. The entire product portfolio extends to 50 different models. The export quota is around 80 percent. The HanseYachts AG share is listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE000A0KF6M8).

Market Capitalisation:	EUR 86 M
Exchange Segment:	General Standard
Principal Shareholders:	79.53% Aurelius Group https://aurelius-group.com/en/equity-opportunities/companies/
Sales:	EUR 121 M*; EUR 160 M**
Earnings (after Taxes):	EUR -10 M*, EUR +1 M**
Earnings per Share:	EUR -0.64*; EUR +0.09**

*preliminary 2020/21

**expected 2021/22

Cogia AG



Cogia AG is a provider of AI-based and patented semantic solutions in the field of “Big Data Analytics” as well as media monitoring technology. The company offers products for intelligent information search, organization and analysis for web and social media. The aim is to support companies and organizations in the optimal utilization of available information by using automated processes to index the content of existing digitized knowledge and prepare it in a structured manner.

In 2020, the company expanded its product portfolio to include a new solution in the area of “customer experience”: the Cogia Customer Experience Manager (Cogia CXM). Cogia AG supports customers from public authorities, business, agencies and NGOs – among them Fortune 500 companies – in the evaluation of Internet information.

The shares of Cogia AG are listed at the Düsseldorf Stock Exchange (ISIN: DE000A3H2226).

Comgest S.A.



Comgest S.A. is an independent, international asset management group, which since its creation in 1985, has pursued a long-term 'Quality Growth' and responsible investment style. Comgest S.A. serves investors who share its long-term investment horizon around the world.

As an asset manager whose equity is held solely by its employees, Comgest S.A. is a special success story in the industry. Eva Fornadi will present the special way of working of the portfolio managers and the investment style of Comgest S.A. and report from daily practice.

The speaker Eva Fornadi is co-portfolio manager of the company's successful European strategies and ranks among the top 30 female fund managers worldwide, according to Citywire. Eva Fornadi joined Comgest S.A. in 2005 and specializes in European companies as a portfolio manager and analyst. She is co-leader of the Europe Smaller Companies and Europe Opportunities strategies.

Edmond de Rothschild Asset Management S.A.



**EDMOND
DE ROTHSCHILD**

The Edmond de Rothschild Group, founded in 1953, specialises in asset management and private banking and has EUR 155 B of assets under management. The Group currently employs 2,500 people and has 32 offices worldwide and serves an international clientele of families, entrepreneurs and institutional investors.

The Group is also active in Corporate Finance, Sustainable Investments, Private Equity, Infrastructure, Real estate and Fund services. The Asset Management division is characterised by a comprehensive product offering in the equity and fixed income area. A particular focus is on infrastructure debt, sustainable investments (ESG), climate change (Green New Deal), new technologies (Big Data) and emerging market debt.

In Real Estate the Group has many years of expertise in managing institutional Real Estate funds (including Euro Industrial, Affordable Homes) and, since 2020, a complementary Real Estate Debt strategy for this target group. In addition, they offer a broadly diversified variety of strategies via a Private Equity platform, ranging from ESG and impact investing to emerging markets solutions.

RAMFORT GmbH

RAMFORT®

RAMFORT GmbH is a family business founded in 2003 by Mr. Björn Wittke, which is still owner-managed today. The company is an asset management company focusing on investments in real estate. Managed are exclusively investments in own portfolio properties and company participations. With its roots and headquarters in Regensburg, RAMFORT GmbH manages and invests in real estate and real estate businesses throughout Germany.

RAMFORT GmbH with its 100 percent participation in SafelInvest GmbH, is indirectly involved in its five subsidiaries as a portfolio holder of office and commercial real estate. RAMFORT GmbH is structured as a financing holding company which, through its subsidiaries, specializes in the portfolio development and refurbishment of value-added commercial properties. The refurbishment and subsequent reduction of vacancy rates allows considerable potential for value enhancement to be leveraged. The portfolio properties held by the company structure currently have over 40,000 m² of office and commercial space, in which the measures for sustainable value enhancement are currently being implemented.

To support the individual measures in the area of refurbishment and expansion, RAMFORT GmbH 2021 has issued the first bond with a volume of EUR 10 M and a coupon of 6.75 percent.

PRUVIA GmbH

PRUVIA 

WSTRE⁷
Advisory

PRUVIA GmbH is an innovative startup from the clean tech sector. The company has developed a breakthrough, innovative technology for recycling plastic waste into a high-quality synthetic oil. This oil is primarily used to produce new plastic, but can also be used to produce other petroleum-based products.

Replacing fossil resources with the company's synthetic oil thus enables an infinite circular economy in the plastics industry. This solves the increasing problem of plastic pollution and also massively reduces CO2 emissions. In addition, the company's MLM-R[®] system achieves an average IRR of 22.2% and an average payback period of only 4.5 years, thus managing a unique combination of environmental protection and profitability. The proof-of-concept of the process as well as the MLM-R[®] technology has been successfully verified with a pilot plant. The technology is protected by a successful patent application. The technical design of the plant allows direct scaling to industrial size. The PRUVIA MLM-R[®] technology reconciles climate protection and economy through innovation and scalability.

GuardBox SE



GuardBox SE is a holding company that acquires and manages investments in companies that offer products and services in the field of mobile security and entertainment. Experienced management and a convincing digital strategy will lead to a sustainable development of our shareholder value.

The current focus is on developing and marketing the Guardmine, a revolutionary smart mobile safe that uniquely combines multiple digital technologies in one device: mobile safe with GPS tracking, powerbank, mobile speaker and camera security system. GuardBox SE addresses both the B2C and B2B market. Especially telecom companies and hotel groups are showing great interest in our white label solutions.

The business model consists of two strategies. On the one hand, the Guardmine itself is sold at a margin above 50%. Additionally, the lifetime value is doubled by selling digital services through our online platform, such as activating the built-in eSIM card for GPS tracking and video data transfer to the cloud. The digital platform also allows for selling marketing space and digital products.

Market Capitalisation:	EUR 9 M (as of October 6, 2021)
Exchange Segment:	Berlin Stock Exchange (ISIN: DE000A2QB6Y9)
Principal Shareholders:	Dr. Marinus Bouwman, Merx Beteiligungs GmbH
Sales:	EUR 1.5 M* / EUR 3.1 M**
Earnings (after Taxes):	EUR 0.2 M* / EUR 0.5 M**
Earnings per Share:	EUR 0.09* / EUR 0.22**
Dividend per Share:	no dividend
Dividend Yield:	no dividend

* expected 2022

** expected 2023



Disclaimer

The Capital Market Conferences Family Office Day are a platform for companies to present their business models and future projects to potential investors and for economic dialogue between representatives and investors. The conferences are financed by the presenting companies. None of the information given is connected to any investment targets, financial situations or requirements of the recipients. All presentations, opinions or commentary are personal views of the author. None of the presentations given and comments made at the Capital Market Conferences Family Office Day constitute or form parts of any offer or invitation to sell or purchase securities or stakes in a company. They do not replace professional, individual investment consulting. The host of Family Office Day Capital Market Conferences Advantage Finance and any related staff disclaim liability for any content or statements made during the presentations. The presentations are not reviewed in advance. Any content neither constitutes a solicitation of an offer nor is it a prospectus in the sense of the Austrian Capital Market Act (Kapitalmarktgesetz), the Austrian Stock Exchange Act (Börsegesetz), the Securities Trading Act or any other applicable law. Neither this publication nor its contents nor any copy of this publication may be changed or distributed to third parties (especially those located in the US) without the host's permission. The host collects and saves customer data which is needed for the invitations to the conferences and uses personal data solely for business activity of Advantage Finance. The presentations and discussion panels will take place in Vienna with an Online-Live-Broadcast. By attending on site you give your consent that you might unintentionally appear in the live stream though it is not our intention to film the audience. By participating at the conference you give your consent that the host Advantage Finance is entitled to share information (only company – no e-mail and phone number) with the presenting companies. If you do not give your consent, please explicitly inform us in advance, because discretion is very important for us! By participating at the Capital Market Conferences Family Office Day, you agree to be bound by the foregoing instructions and restrictions.



Reply/Registration

Please register until 15 October 2021 via e-mail: **investorenkonferenzen@familyofficeday.at**

First Name/Surname:

Family/Institution:

I will participate in Vienna

I will participate Online

I want one-on-one meetings with the following companies:

HBM Healthcare Investments AG

We Ship Fulfillment GmbH

BB Biotech AG

HanseYachts AG

MagForce AG

Cogia AG

Valneva SE

Comgest S.A.

Cellestia Biotech AG

Edmond de Rothschild Asset Management S.A.

Accanis Biotech F&E GmbH & Co KG AG

RAMFORT GmbH

Topadur Pharma AG

GuardBox SE

PRUVIA GmbH

Please invite the following family members/investors to the conference:

.....

By participating at the conference you give your consent that the host Advantage Finance is entitled to share information (only company – no name, e-mail and no phone number) with the presenting companies. If you do not give your consent, please explicitly inform us in advance, because discretion is very important for us!

SEE YOU AT THE FAMILY OFFICE DAY



FAMILY OFFICE DAY

CAPITAL MARKET CONFERENCES

www.familyofficeday.at